DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technologyApproval represents critical advancement in early intervention for multiple myelomaSAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult ...

Key Takeaways Keytruda accounts for nearly 50% of MRK's pharma revenues, driving growth across cancer indications globally. Early-stage lung cancer and metastatic uptake are fueling strong sales momentum for Keytruda. Heavy reliance on Keytruda poses risks as the 2028 loss of exclusivity draws closer.Merck’s (MRK) primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts for almo ...

Key Takeaways PFE's non-oncology Q2 outlook includes growth in Vyndaqel and Nurtec alongside mixed vaccine trends. Primary Care faces IRA pricing pressure on Eliquis and softer international demand for Prevnar. Comirnaty's Q1 rebound raises hopes, while Paxlovid and Abrysvo may reflect lower demand.Pfizer (PFE) is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which account for around 25% of the company’s total revenues. Pfizer’s key oncology drugs ar ...

Dr. Reddy’s Laboratories (RDY) Q1 2026 Earnings Call July 23, 2025 10:00 AM ET Company ParticipantsRicha Periwal - Head - Corporate Analytics, Corporate Strategy & IRM V Narasimham - CFO & Member of the Management CouncilErez Israeli - CEOAmey Chalke - VP & Sector Lead - Healthcare & PharmaceuticalHarith Ahamed - Director - Equity ResearchBino Pathiparampil - Head of ResearchSaion Mukherjee - MD & Head - Equity ResearchSurya Patra - SVPConference Call ParticipantsNeha Manpuria - Senior AnalystDamayanti Kera ...

Dr. Reddy’s Laboratories (RDY) Q1 2026 Earnings Call July 23, 2025 10:00 AM ET Speaker0Good morning, good evening, and a warm welcome to all. Thank you for joining us for doctor Reddy's q one FY twenty six earnings conference call. We truly appreciate your time and participation. Joining us today are members of the leadership team, mister Erez Israeli, our CEO, mister MV Narsimham, our CFO, and the IR team.Earlier today, we released our quarterly financial results. These are now available on our website for ...

Shield Therapeutics (1JS) Trading Update July 23, 2025 10:00 AM ET Speaker0Good afternoon, and welcome to the Shield Therapeutics PLC Q2 Trading Update. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and they can be submitted at any time using the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. Company may not be in a position to answer every question it receives during the meeting itself.Howe ...

Core Insights - Amgen (AMGN) and Novo Nordisk (NVO) are leading companies in the pharmaceutical industry, with Amgen focusing on oncology and rare diseases, while Novo Nordisk specializes in diabetes and obesity treatments [1][2] Group 1: Amgen (AMGN) - Amgen has a diverse portfolio with strong growth products such as Repatha, Prolia, and Xgeva, which have helped offset declines in legacy drug sales [3][4] - The acquisition of Horizon Therapeutics has expanded Amgen's rare disease offerings, adding drugs like Tepezza and Krystexxa [4] - Amgen is developing an obesity drug, MariTide, which is in late-stage trials and has shown promising weight loss results, although slightly below investor expectations [5][6] - The company has a strong pipeline with drugs targeting various therapeutic areas, including bemarituzumab for gastric cancer and olpasiran for cardiovascular disease [7] - Amgen has launched biosimilars for popular drugs and is developing more in the oncology space [8] - Despite growth prospects, Amgen faces pricing pressures and expected declines in sales for some of its best-selling drugs due to patent expirations [9] Group 2: Novo Nordisk (NVO) - Novo Nordisk leads the GLP-1 market with a 54% market share, driven by successful products like Ozempic and Wegovy [12] - The company is expanding its manufacturing capacity to support the growing demand for its diabetes and obesity treatments [13] - Novo is pursuing new indications for semaglutide, which could enhance its market position [14] - However, the company faces competition from Eli Lilly and challenges related to disappointing data from its next-generation obesity drug, CagriSema [15][16] - A leadership transition is underway as CEO Lars Fruergaard Jørgensen steps down, which may impact investor sentiment [16] - Novo is also working to expand its rare disease portfolio, with plans to submit a regulatory filing for Mim8 [17] Group 3: Financial Performance and Valuation - Amgen's 2025 sales and EPS estimates suggest a 5% year-over-year increase, with positive revisions in the past 60 days [18] - In contrast, Novo's 2025 sales and EPS estimates imply a significant increase of around 20% and 21%, respectively, although 2026 EPS estimates have declined [20] - Year-to-date, Amgen's shares have gained 17%, while Novo's shares have dropped 22%, against a 3% decline in the industry [21] - From a valuation perspective, Novo Nordisk trades at a higher P/E ratio of 15.51 compared to Amgen's 14.5 [22] - Amgen offers a higher dividend yield of 3.1% compared to Novo's 2.5% [26] Group 4: Investment Considerations - Both companies hold a Zacks Rank 3 (Hold), making it challenging to choose one over the other [28] - Amgen is viewed as a better pick due to its diversified portfolio and attractive valuation, despite facing short-term challenges [29] - Novo Nordisk's strong revenue growth in the GLP-1 space is tempered by limited diversification and ongoing challenges [30]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores serve as complementary indicators to the Zacks Rank, aiding investors in selecting stocks with high potential for market outperformance [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on value, growth, and momentum characteristics, with higher scores indicating better chances of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks with upward or downward price trends, utilizing one-week price changes and monthly earnings estimate changes to identify optimal buying times [5] VGM Score - Combines the three Style Scores to highlight stocks with attractive value, strong growth forecasts, and promising momentum, serving as a key indicator alongside the Zacks Rank [6] Zacks Rank Integration - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9] Company Spotlight: Array Technologies, Inc. (ARRY) - Array Technologies is a biopharmaceutical company focused on targeted small molecule drugs for cancer treatment, with a marketed therapy for melanoma [11] - ARRY holds a Zacks Rank of 2 (Buy) and a VGM Score of A, with a Momentum Style Score of B, reflecting a 10.8% increase in shares over the past four weeks [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate increase of $0.03 to $0.66 per share highlight ARRY's strong performance potential [12][13]

A downtrend has been apparent in Amphastar Pharmaceuticals (AMPH) lately with too much selling pressure. The stock has declined 13.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

President Donald Trump's art of the deal seemed to play out in real time on Tuesday.Trump announced what he called a "massive" trade agreement with Japan over his Truth Social platform Tuesday night, which the president said includes a 15% tariff rate and $550 billion in investments. But the details of that deal on a card on Trump's desk shows discrepancies and last-minute edits, according to a photo posted by by Dan Scavino, the White House deputy chief of staff.The card on Trump's desk displays a 10% tari ...